thanks for the link shanshan..in the last 12 months only 4 bio...

thanks for the link shanshan..in the last 12 months only 4 bio stocks have raised more than PRIMA's $12mill.. and your telling me PRIMA PRR has a market cap of only 10mill when other stocks are sitting around 50mill market cap..this stock should be much higher, in time the market should realise hopefully.

things on track to date..april 28th night is a big day for holders.

CAPITAL RAISINGS
Despite claims that biotechnology is about to disappear and there are no funds available
for the high risk sector, at least $370 million has been raised in the past 12 months.
Biotech Daily has compiled the list below of known capital raisings published by
companies in the sector. It is believed that private biotechnology funds and life sciences
companies have raised other significant funds, but that data is not publicly available.
The largest amount raised was the closing of the GBS Venture Partners fund with $122.5
million of which $11.5 million is also included in Peplin’s $46 million October 2008 raising.
Brandon Capital has raised $50 million. Intersuisse and Strategic Life Sciences have been
active but have not disclosed the amounts they have raised. Biotech Daily called Starfish
Ventures but did not have a comment at the time of publication.
There may be some double accounting in that funds raise the money and then contribute
to company raisings, but a total of at least $42.914 million has been raised by listed
companies since January this year not including GBS Ventures’ $122.5 million.
The cumulative total raised over the last 12 months not including venture capital raisings
is $176.917 million, with at least a further undisclosed $31 million raised by other venture
capital firms. A further private raising of up to $100 million is expected “soon”.
California’s Essex Woodlands Health Ventures raised $US900 million ($A1,280 million) for
drug, device and service companies in North America, Europe and Asia on March 30,
2009 and the Swiss and UK-based Index Ventures closed a EUR350 million ($A661
million) fund for early stage investment in Europe, the US and Israel on March 3, 2009.
For the record:
CBio $1.5m
Incitive $784k; April 2, 2009
Polartechnics $2.5m; Apr 1, 2009
Biomd $426k; Apr 1, 2009
Mesoblast $10.81m; Mar 30, 2009
GBS Venture Partners $122.5m; Mar 19, 2009
Healthlinx $3m; Mar 25, 2009; $144k; Mar 24, 2009
Prima $12m; Mar 11, 2009
Tissue Therapies $1.2m; Mar 4, 2009
Eastland $4-6m (being raised); Mar 3, 2009
Medical Therapies $450k; Feb 23, 2009
Karmelsonix $1m; Feb 23 2009
Bionomics $4m; Feb 5, 2009
Ellex $1.6m; Jan 16, 2009
Benitec $1m; Jan 2009
Safety Medical $9.5m; Dec 17, 2008
OMI $503k; Nov 7, 2008
Peplin $US30.7m ($A46m); Oct 2008
Fluorotechnics $9m; Oct 2008
Chemgenex $13m; Sep 17, 2008
Spinifex $12m; Sep 2008
Heartware $30m; May 2008
Phosphagenics $9m; May 2008
Genera Biosystems $5m; June 11, 2008